121 related articles for article (PubMed ID: 18466669)
1. The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats.
Millan MJ; Gobert A; Panayi F; Rivet JM; Dekeyne A; Brocco M; Ortuno JC; Di Cara B
Int J Neuropsychopharmacol; 2008 Dec; 11(8):1105-22. PubMed ID: 18466669
[TBL] [Abstract][Full Text] [Related]
2. Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats.
Di Cara B; Panayi F; Gobert A; Dekeyne A; Sicard D; De Groote L; Millan MJ
Int J Neuropsychopharmacol; 2007 Jun; 10(3):383-99. PubMed ID: 16925890
[TBL] [Abstract][Full Text] [Related]
3. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization.
Dekeyne A; Brocco M; Loiseau F; Gobert A; Rivet JM; Di Cara B; Cremers TI; Flik G; Fone KC; Watson DJ; Papp M; Sharp T; Serres F; Cespuglio R; Olivier B; Chan JS; Lavielle G; Millan MJ
J Pharmacol Exp Ther; 2012 Mar; 340(3):765-80. PubMed ID: 22178753
[TBL] [Abstract][Full Text] [Related]
4. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis.
Millan MJ; Di Cara B; Dekeyne A; Panayi F; De Groote L; Sicard D; Cistarelli L; Billiras R; Gobert A
J Neurochem; 2007 Feb; 100(4):1047-61. PubMed ID: 17266737
[TBL] [Abstract][Full Text] [Related]
5. The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis.
Millan MJ; Gobert A; Roux S; Porsolt R; Meneses A; Carli M; Di Cara B; Jaffard R; Rivet JM; Lestage P; Mocaer E; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Oct; 311(1):190-203. PubMed ID: 15146031
[TBL] [Abstract][Full Text] [Related]
6. Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety.
Basso AM; Bratcher NA; Gallagher KB; Cowart MD; Zhao C; Sun M; Esbenshade TA; Brune ME; Fox GB; Schmidt M; Collins CA; Souers AJ; Iyengar R; Vasudevan A; Kym PR; Hancock AA; Rueter LE
Eur J Pharmacol; 2006 Jul; 540(1-3):115-20. PubMed ID: 16765941
[TBL] [Abstract][Full Text] [Related]
7. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists.
Loiseau F; Millan MJ
Eur Neuropsychopharmacol; 2009 Jan; 19(1):23-33. PubMed ID: 18793829
[TBL] [Abstract][Full Text] [Related]
8. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
Wesołowska A; Nikiforuk A
Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
[TBL] [Abstract][Full Text] [Related]
9. Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice.
Smith DG; Davis RJ; Rorick-Kehn L; Morin M; Witkin JM; McKinzie DL; Nomikos GG; Gehlert DR
Neuropsychopharmacology; 2006 Jun; 31(6):1135-45. PubMed ID: 16205780
[TBL] [Abstract][Full Text] [Related]
10. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.
Gobert A; Di Cara B; Cistarelli L; Millan MJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):338-46. PubMed ID: 12649387
[TBL] [Abstract][Full Text] [Related]
11. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Millan MJ; Brocco M; Gobert A; Dekeyne A
Psychopharmacology (Berl); 2005 Feb; 177(4):448-58. PubMed ID: 15289999
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent.
Millan MJ; Brocco M; Gobert A; Dorey G; Casara P; Dekeyne A
Neuropsychopharmacology; 2001 Oct; 25(4):585-600. PubMed ID: 11557172
[TBL] [Abstract][Full Text] [Related]
13. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
14. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant/anxiolytic potential and adverse effect liabilities of melanin-concentrating hormone receptor 1 antagonists in animal models.
Chaki S; Shimazaki T; Nishiguchi M; Funakoshi T; Iijima M; Ito A; Kanuma K; Sekiguchi Y
Pharmacol Biochem Behav; 2015 Aug; 135():154-68. PubMed ID: 26044968
[TBL] [Abstract][Full Text] [Related]
16. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties.
Millan MJ; Hjorth S; Samanin R; Schreiber R; Jaffard R; De Ladonchamps B; Veiga S; Goument B; Peglion JL; Spedding M; Brocco M
J Pharmacol Exp Ther; 1997 Jul; 282(1):148-61. PubMed ID: 9223550
[TBL] [Abstract][Full Text] [Related]
17. The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity.
Bertaina-Anglade V; Enjuanes E; Morillon D; Drieu la Rochelle C
J Pharmacol Toxicol Methods; 2006; 54(2):99-105. PubMed ID: 16750402
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis.
David DJ; Klemenhagen KC; Holick KA; Saxe MD; Mendez I; Santarelli L; Craig DA; Zhong H; Swanson CJ; Hegde LG; Ping XI; Dong D; Marzabadi MR; Gerald CP; Hen R
J Pharmacol Exp Ther; 2007 Apr; 321(1):237-48. PubMed ID: 17237257
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Brocco M; Dekeyne A; Papp M; Millan MJ
Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
[TBL] [Abstract][Full Text] [Related]
20. The scopolamine-induced impairment of spatial cognition parallels the acetylcholine release in the ventral hippocampus in rats.
Mishima K; Iwasaki K; Tsukikawa H; Matsumoto Y; Egashira N; Abe K; Egawa T; Fujiwara M
Jpn J Pharmacol; 2000 Oct; 84(2):163-73. PubMed ID: 11128039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
